Date issuedProductSafety information
21/05/41 Olmepress (Olmesartan)

Restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Olmepress (Olmesartan).CLICK HERE​

15/04/41 Kyprolis® ( Carfilzomib)

Kyprolis (carfilzomib) – New Safety Information: Risk of Progressive Multifocal Leukoencephalopathy (PML) and Hepatitis B Virus (HBV) Reactivation.CLICK HERE

11/04/41 Esbriet® (Pirfenidone)

Important Safety Update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI).CLICK HERE

17/03/41 FEGONA®

FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception ​. CLICK HERE​​​​​

22/02/41 Zofran®

Direct Healthcare Professional Communication on the risk of birth defects from the recently published epidemiological studies for Zofran® (Ondansetron)  . CLICK HERE​​​​​​

20/01/41 Methotrexate "Ebewe”

​Recommendations to avoid potentially fatal dosing errors when using methotrexate “METHOTREXATE "EBEWE “ for autoimmune diseases ​CLICK HERE​​​​​

12/01/41 Roaccutne

Roaccutne (isotretinoin): An update on neuropsychiatric disorders.CLICK HERE​​​​

25/12/40 soliqua (lixisenatide /insuline glargin) soliqua

(lixisenatide /insuline glargin):  Important information on dosing.CLICK HERE​​​

25/12/40 Advaquin ( levofloxacin)

Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection.CLICK HERE​​​

07/12/40 Gilenya (fingolimod)

Gilenya (fingolimod)): New contraindication in pregnant women and in women of childbearing potential not using effective contraception.CLICK HERE​​​​

12345...الأخيرة